Next Article in Journal
The Anti-Inflammatory Effect of Bovine Bone-Gelatin-Derived Peptides in LPS-Induced RAW264.7 Macrophages Cells and Dextran Sulfate Sodium-Induced C57BL/6 Mice
Previous Article in Journal
Description of a Newly Isolated Blautia faecis Strain and Its Benefit in Mouse Models of Post-Influenza Secondary Enteric and Pulmonary Infections
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 14
Issue 7
10.3390/nu14071480
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Relationship between Habitual Intake of Vitamins and New-Onset Prediabetes/Diabetes after Acute Pancreatitis

by
Claire F. Norbitt
,
Wandia Kimita
,
Sakina H. Bharmal
,
Juyeon Ko
and
Maxim S. Petrov
*
School of Medicine, University of Auckland, Auckland 1023, New Zealand
*
Author to whom correspondence should be addressed.
Nutrients 2022, 14(7), 1480; https://doi.org/10.3390/nu14071480
Submission received: 17 February 2022 / Revised: 29 March 2022 / Accepted: 29 March 2022 / Published: 1 April 2022
(This article belongs to the Section Micronutrients and Human Health)
Versions Notes

Abstract

:
Vitamins have many established roles in human health. However, the role of habitual dietary intake of vitamins in glucose homeostasis in individuals after acute pancreatitis (AP) is yet to be elucidated. The aim was to investigate the associations between habitual intake of fat- and water-soluble vitamins/vitamers and markers of glucose metabolism (fasting plasma glucose (FPG), homeostasis model assessment insulin resistance (HOMA-IR) index, and homeostasis model assessment β-cell function (HOMA-β)) in individuals after AP. A total of 106 participants after AP were included in this cross-sectional study and were grouped based on glycaemic status: new-onset prediabetes/diabetes after AP (NODAP), pre-existing prediabetes/type 2 diabetes (T2DM), and normoglycaemia after AP (NAP). Habitual intake of seven fat-soluble vitamins/vitamers and seven water-soluble vitamins were determined by the EPIC-Norfolk food frequency questionnaire. Multiple linear regression analyses were conducted using five statistical models built to adjust for covariates (age, sex, daily energy intake, visceral/subcutaneous fat volume ratio, smoking status, daily alcohol intake, aetiology of AP, number of AP episodes, cholecystectomy, and use of antidiabetic medications). In the NODAP group, three fat-soluble vitamins/vitamers (α-carotene, β-carotene, and total carotene) were significantly associated with HOMA-β. One water-soluble vitamin (vitamin B3) was also significantly associated with HOMA-β in the NODAP group. None of the studied vitamins were significantly associated with FPG or HOMA-IR in the NODAP group. Prospective longitudinal studies and randomised controlled trials are now warranted to investigate if the observed associations between vitamin/vitamer intake and NODAP are causal and to unveil the specific mechanisms underlying their involvement with NODAP.

1. Introduction

Vitamins and vitamers are essential micronutrients required to maintain metabolic health [1,2]. There are 13 known vitamins and several vitamers required in small quantities for metabolic health (e.g., energy metabolism, antioxidant function, and enzymatic functions) [2,3,4,5,6,7,8]. There are two subtypes of vitamins classified by their solubility—fat-soluble and water-soluble vitamins. Most vitamins (such as vitamins A, C, E, and K, majority of B complex vitamins) are not endogenously synthesised by the body and are predominantly obtained through the diet [5]. The structural differences between the groups of vitamins influence their method of absorption [3]. Low intake of vitamin-rich foods or reduced vitamin absorption can cause oxidative stress-driven disorders such as insulin resistance [9,10], β-cell dysfunction [11], and metabolic syndrome [8,12]. Reduced fat- and water-soluble vitamin intake is also associated with type 2 diabetes. For instance, a large prospective cohort study showed that low intake of fat-soluble vitamins E and K increased risk of this type of diabetes [13]. Other studies demonstrated that low intake of water-soluble vitamins C, B2, and B9 was associated with increased risk of type 2 diabetes [14,15].
Another example of a disease marked by oxidative stress is acute pancreatitis (AP). Damage to pancreatic cells during an attack of AP can cause subsequent endocrine and exocrine dysfunctions [16,17]. A systematic literature review and meta-analysis by the COSMOS group showed that exocrine pancreatic dysfunction occurs in 29% of patients following an episode of AP [18]. Exocrine pancreatic insufficiency impairs digestion and absorption of food and nutrients, resulting in deficiency of vitamins [19]. A large cohort study conducted by the COSMOS group demonstrated that individuals after AP with exocrine pancreatic insufficiency had a significantly increased risk of new-onset diabetes after AP, irrespective of the disease severity [20]. New-onset prediabetes/diabetes after AP (NODAP) develops in about 40% of individuals after an episode of AP and individuals with NODAP are characterised by chronic low-grade inflammation, impaired lipid metabolism, iron metabolism, and islet dysfunction [17,21,22]. NODAP is a clinically distinct entity to type 2 diabetes, yet often misclassified and misdiagnosed as type 2 diabetes [21,23,24]. Individuals with NODAP have worse glycaemic control [21], increased need for insulin therapy [21], higher incidence of pancreatic cancer [25], and higher hospitalisations and mortality than individuals with type 2 diabetes [26]. Nonetheless, there are no specific guidelines for optimal nutrition therapy for new-onset diabetes after AP, with patients typically receiving generalised type 2 diabetes nutrition advice focusing on macronutrient distribution, portion sizes, and intake of minimally processed foods [27,28]. Emerging evidence suggests a role of micronutrients, particularly mineral intake, in the development of new-onset diabetes after AP [29,30]. To date, intake of other micronutrients (specifically vitamin intake) has never been investigated in the context of new-onset diabetes after AP.
Therefore, this study aimed to investigate the relationships between habitual vitamin intake and fasting plasma glucose (FPG), homeostasis model assessment insulin resistance (HOMA-IR) index, and homeostasis model assessment β-cell function (HOMA-β) index in individuals after AP.

2. Materials and Methods

2.1. Study Design

This study was a cross-sectional investigation of individuals after an episode of AP. This study was part of the ANDROMEDA (Assessment of Nutritional and DietaRy factOrs in Metabolic Disorders after pAncreatitis) project conducted by the COSMOS group. Ethical approval for this study was granted by the Health and Disability Ethics committee (13/STH/182). Individuals were eligible to participate if they had a primary diagnosis of AP (defined by international guidelines [31]), were aged 18 years or older, resided in Auckland (New Zealand) throughout the study, and gave informed consent for participation. Individuals were not eligible to participate in the study if they had history of type 1 or gestational diabetes, a diagnosis of chronic pancreatitis, intra-operative diagnosis of pancreatitis, post-endoscopic retrograde cholangiopancreatography pancreatitis, pregnancy throughout or after AP attack, history of steroid use, malignancy, coeliac disease, or cystic fibrosis.

2.2. Study Groups

According to the ‘DEP criteria’, individuals were categorised into three non-overlapping groups based on HbA1c and FPG [32].
Normoglycaemia after AP (NAP) group: individuals who had HbA1c < 5.7% (39 mmol/mol) and/or FPG < 100 mg/dL (5.6 mmol/L) at the time of their primary attack of AP and at the time of the study were deemed to have NAP.
Type 2 diabetes or prediabetes (T2DM) group: individuals who had an HbA1c ≥ 5.7% (39 mmol/mol) and/or FPG ≥ 100 mg/dL (5.6 mmol/L) at the time of their primary attack of AP and at the time of their participation in the study were deemed to have T2DM.
New-onset diabetes or prediabetes after AP (NODAP) group: individuals who were normoglycaemic prior to and throughout their primary attack of AP and had HbA1c ≥ 5.7% (39 mmol/mol) and/or FPG ≥ 100 mg/dL (5.6 mmol/L) at follow-up were deemed to have NODAP. Participants who had FPG > 100 mg/dL (5.6 mmol/L) but HbA1c < 5.7% (39 mmol/mol) during their primary attack of AP were not considered in this study to account for effects of transient stress hyperglycaemia [17].

2.3. Ascertainment of Vitamin Intake

The EPIC-Norfolk food frequency questionnaire (FFQ) was used to collect habitual dietary intake data of study participants in the 12 months prior to recruitment [33]. The extensively validated, semi-quantitative, and self-administered FFQ assesses the frequency of intake of 130 consumed foods. Additionally, information on types and brands of commonly consumed foods was collected (cereal, milk, meat, and cooking oils). Data gathered from the FFQ were then analysed using the FETA (FFQ EPIC Tool for Analysis) software (V2.53, University of Cambridge, Cambridge, UK) to ascertain daily intake of seven fat-soluble vitamins and vitamers (α-carotene (µg), β-carotene (µg), retinol (µg), total carotene (µg) vitamin A/total retinol equivalents (µg), vitamin D (µg), and vitamin E (mg)), and seven water-soluble vitamins (vitamin B1 (mg), vitamin B2 (mg), vitamin B3 (mg), vitamin B6 (mg), vitamin B9 (µg), vitamin B12 (µg), vitamin C (mg)). Habitual vitamin intake was measured from dietary intake only and intake from vitamin supplementation was excluded from this study. FFQ data were excluded from the study if the FFQ was incomplete (ten or more questions were left unanswered) to limit underestimation of habitual intake [33]. If the ratio of estimated total energy intake (estimated from the FFQ data) and estimated basal metabolic rate (calculated by the Harris-Benedict equation) were more than two standard deviations (SD) outside the mean ratio (i.e., <0.28 and >1.82), FFQ data were excluded [33].

2.4. Laboratory Assays

All participants were required to fast 8 h before blood collection by certified phlebotomists. Fresh blood samples were analysed, with HbA1c (mmol/mol), FPG (mmol/L), and fasting insulin (mU/L) measured by LabPlus (International Accreditation New Zealand accredited medical laboratory at Auckland City Hospital). HbA1c was analysed using the boronate affinity chromatography assay (©2015 Roche Products (New Zealand) Ltd., Auckland, New Zealand and Roche Diagnostics NZ Ltd., Auckland, New Zealand). FPG was measured using an enzymatic colourimetric assay (©2015 F. Hoffmann-La Roche Ltd., Basel, Switzerland). Fasting insulin was measured using chemiluminescence sandwich immunoassay (Roche Diagnostics, Auckland, New Zealand). Oxford University’s Homeostasis Model Assessment calculator (HOMA2) was used to estimate HOMA-IR and HOMA-β indices (version 2.2.4 Diabetes Trials Unit, University of Oxford, Oxford, UK).

2.5. Covariates

The COSMOS team collected anthropometric and demographic data from participants. Participants underwent magnetic resonance imaging (MRI) to measure abdominal visceral fat volume (VFV) and subcutaneous fat volume (SFV). A 3T MAGNETOM Skyra scanner (Siemens, Erlangen, Germany) was used to conduct MRI scans at the Centre for Advanced Magnetic Resonance Imaging (University of Auckland, Auckland, New Zealand). Axial T1-weighted volumetric interpolated breath-hold examination Dixon sequence was applied, with participants lying supine and holding breath at maximum expiration, as reported elsewhere [34]. Fat-only images between L2 and L5 vertebral lumbar levels were quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA) [35]. Greyscale pixels of the slice series were converted into binary images using the threshold function of ImageJ, as per the global histogram-derived method [34]. Non-adipose tissue was excluded from the visceral fat measurements. Last, the total number of pixels from the slices series was calculated and multiplied by the pixel area and slice thickness to obtain the VFV and SFV [36]. VFV and SFV were measured by two independent and blinded raters, and the average values of the two measurements were used as the final values of VFV and SFV. The ratio of visceral to subcutaneous fat volume (V/S fat volume ratio) was then calculated. Average daily energy intake (kcal) and alcohol intake (g/day) was obtained using the FFQ and quantified by the FETA software (University of Cambridge, Cambridge, UK) [33]. Tobacco smoking status was recorded as either ‘yes’ or ‘no’ using a standardised questionnaire [37]. Data on antidiabetic medication usage, cholecystectomy, and AP aetiology were obtained from participants’ health records.

2.6. Statistical Analyses

Statistical analyses were performed using SPSS 27.0 software (IBM Corporation, Armonk, NY, USA). One-way ANOVA was used to investigate differences in participants’ characteristics between the study groups (NODAP, T2DM, and NAP). Data were presented as mean (standard deviation) or frequency (percentage), and p values were deemed statistically significant if less than 0.05. Associations between the habitual intake of the investigated fat-soluble and water-soluble vitamins and FPG, HOMA-β, and HOMA-IR were examined for each study group. FPG, HOMA-β, and HOMA-IR were the dependent variables and the vitamin variables were the independent variables. All investigated vitamins/vitamers showed skewed distribution (based on the Shapiro-Wilk test) and therefore were logarithmically transformed to account for non-normal distribution. A total of five statistical models were built for multiple linear regression analyses. Model 1 was unadjusted; model 2 was adjusted for age, sex, and daily energy intake; model 3 was adjusted for variables included in model 2 and V/S fat volume ratio; model 4 was adjusted for variables included in model 3 as well as smoking status and daily alcohol intake; model 5 was adjusted for variables included in model 4 and aetiology of AP, number of AP episodes, cholecystectomy, and use of antidiabetic medications. Data were presented as R2, unstandardised B, p value, and 95% confidence interval. P values less than 0.05 were deemed statistically significant in all analyses, and data were not corrected for multiple tests.

3. Results

3.1. Study Cohort

Of the 117 individuals who enrolled in the study, 106 participants were used for analyses. 11 participants were excluded for more than 10 unanswered FFQ questions and estimated basal metabolic exceeding two SDs outside the mean ratio. Of the 106 included participants, 37 participants made up the NODAP group, 37 the T2DM group, and 32 the NAP group. The mean time elapsed after an attack of AP was of 26 months. The study groups did not differ significantly in terms of the intake of all the vitamin/vitamers. Other descriptive characteristics are presented in Table 1.

3.2. Fat-Soluble Vitamin Intake and Markers of Glucose Metabolism in the Study Groups

3.2.1. Fasting Plasma Glucose

In the NODAP and T2DM groups, associations between FPG and the investigated fat-soluble vitamins/vitamers were not statistically significant (Table 2).
In the NAP group, FPG was significantly associated with two fat-soluble vitamins/vitamers (retinol and vitamin E). Retinol intake was significantly directly associated with FPG in the most adjusted models (model 4: p = 0.046, model 5: p = 0.038). Vitamin E intake was significantly inversely associated with FPG in model 2 (p = 0.040).

3.2.2. HOMA-β

In the NODAP group, HOMA-β was significantly associated with three fat-soluble vitamins/vitamers (α-carotene, β-carotene, and total carotene). α-carotene was significantly directly associated with HOMA-β in the unadjusted model (model 1: p = 0.034) and adjusted models (model 3: p = 0.042, model 4: p = 0.023, model 5: p = 0.013). β-carotene was significantly directly associated with HOMA-β in the most adjusted models (model 4: p = 0.044, model 5: p = 0.035). Total carotene was significantly directly associated with HOMA-β in the most adjusted models (model 4: p = 0.039, model 5: p = 0.029).
In the T2DM or NAP groups, HOMA-β was not significantly associated with any of the investigated fat-soluble vitamins/vitamers (Table 3).

3.2.3. HOMA-IR

In the NODAP, T2DM and NAP groups, associations between HOMA-IR and the investigated fat-soluble vitamins/vitamers were not statistically significant (Table S1).

3.3. Water-Soluble Vitamin Intake and Markers of Glucose Metabolism in the Study Groups

3.3.1. Fasting Plasma Glucose

In the NODAP group, associations between FPG and the investigated water-soluble vitamins were not statistically significant (Table 4).
In the T2DM group, FPG was significantly associated with three water-soluble vitamins (Vitamin B1, vitamin B2, and vitamin B12) (Table 4). Vitamin B1 was significantly inversely associated with FPG in adjusted model 4 only (p = 0.036). Vitamin B2 was significantly inversely associated with FPG in adjusted models (model 2: p = 0.030, model 3: p = 0.041, model 4: p = 0.046). Vitamin B12 was significantly inversely associated with FPG in the unadjusted model (model 1: p = 0.001) and adjusted models (model 2: p = 0.002, model 3: p = 0.003, model 4: p = 0.024).
In the NAP group, FPG was significantly associated with one water-soluble vitamin (vitamin B3). Vitamin B3 was significantly inversely associated with FPG in adjusted model 2 (p = 0.030).

3.3.2. HOMA-β

In the NODAP group, HOMA-β was significantly associated with one water-soluble vitamin (vitamin B3) (Table 5). Vitamin B3 was significantly directly associated with HOMA-β in the most adjusted models (model 4: p = 0.035, model 5: p = 0.041).
In the T2DM and NAP groups, associations between HOMA-β and the investigated water-soluble vitamins were not statistically significant.

3.3.3. HOMA-IR

In the NODAP group, T2DM and NAP groups, associations between HOMA-IR and the investigated water-soluble vitamins were not statistically significant Table S2.

4. Discussion

The present study was the first to investigate the associations between a comprehensive vitamin profile and markers of glucose metabolism (FPG, HOMA-β, and HOMA-IR) in individuals after an attack of AP. A key finding of this study was that, of the seven fat-soluble vitamins/vitamers, significant direct associations between habitual intake of fat-soluble vitamers α-carotene, β-carotene, and total carotene and HOMA-β were found in the NODAP group. Also, of the seven water-soluble vitamins, a significant direct association was observed between vitamin B3 and HOMA-β in individuals with NODAP.

4.1. Fat-Soluble Vitamins

Fat-soluble vitamins (vitamins A, D, E, and K) are hydrophobic compounds and, therefore, are insoluble in the aqueous environment of the gastrointestinal tract [3]. Fat-soluble vitamins are stored in the liver and adipose tissue and, hence, are very slowly excreted from the body. Therefore, very high intakes of fat-soluble vitamins can be detrimental to health [3,38]. Fat-soluble vitamin deficiencies are rare; however, insufficiency may occur in sub-populations including individuals with very low fat intake, low energy intake, or vegetarian/vegan diets [38]. Due to the dependence on dietary fat intake for absorption of fat-soluble vitamins, individuals with malabsorptive conditions, such as exocrine pancreatic dysfunction (EPD), may also develop subsequent deficiencies in these vitamins [19,39,40].
Vitamin A is available in the diet in two forms—retinol (preformed vitamin A) and provitamin carotenoids [41]. There are several forms of carotenoids, with α-carotene and β-carotene being among the most abundant in the human diet and body [41]. Carotenoids are endogenously converted into retinol and contribute to overall vitamin A status. They have potent antioxidant properties that have been found to have a beneficial role in eye health, cognitive function, and the prevention of several diseases including cardiovascular diseases and cancer [42,43]. Dietary carotenoids have also been shown to be associated with the incidence of type 2 diabetes. Quansah et al. observed that increased intake of α-carotene had a 48% and 39% reduction in diabetes risk in Korean men and women, respectively [44]. Additionally, β-carotene intake also reduced the risk of diabetes in men (though no association was found in women) [44]. Another large prospective study showed that higher dietary intake of α-carotene (0.7 mg/day) was associated with a 15% lower risk of type 2 diabetes and β-carotene (3.5 mg/day) was associated with a 22% reduced risk of diabetes, compared with the lowest quartile of the vitamins [45]. A community-based longitudinal study showed that increasing dietary intake of β-carotene by 1.4 mg/day was associated with up to a 34% lower risk of incident diabetes in elderly Swedish men [46]. Men in the highest tertile of β-carotene intake (>1.9 mg/day) at age 70 had up to a 50% lower risk of type 2 diabetes compared with the lowest tertile (<1.0 mg/day) [46]. Additionally, an 0.2 umol/L increase of serum β-carotene at age 50 years was associated with 0.08 units higher insulin sensitivity (determined with the use of euglycaemic-hyperinsulinaemic clamp) in nondiabetic participants at age 70 years. However, insulin secretion was not influenced significantly by serum β-carotene levels [46]. Harari et al. found that serum α-carotene, β-carotene, and total carotenoids were inversely associated with fasting insulin and HOMA-IR in an Australian adult population [47]. Mirmiran et al. also observed that increased dietary intake of β-carotene, but not other carotenoids, was significantly associated with a lower risk of HOMA-IR in Iranian adults [48]. Serum β-carotene concentration was inversely associated with HOMA-IR in middle-aged Japanese individuals [49]. A meta-analysis of prospective observational studies also concluded that dietary intake and circulating concentrations of total carotenoids are associated with beneficial effects on reducing the risk of type 2 diabetes in a population at high risk of type 2 diabetes [49]. In this meta-analysis, β-carotene intake was also consistently inversely associated with diabetes risk.
The present study was the first to investigate the associations between habitual carotenoid intake and insulin traits in individuals after an attack of AP. We found that dietary intake of α-carotene, β-carotene, and total carotene intake was significantly and directly associated with HOMA-β, indicating detrimental effects of deficient carotenoid intake on insulin secretion. Specifically, for every 1% decrease in α-carotene, β-carotene, and total carotene intake, HOMA-β decreased by 0.42%, 0.60%, and 0.63%, respectively. These results indicate that increased intake of α-carotene, β-carotene, and total carotenoids may have beneficial effects on insulin secretion in individuals with NODAP. We found no association with other markers of glucose metabolism (FPG and HOMA-IR). Several intrinsic and extrinsic factors are associated with carotenoid status; therefore, dietary intake may not truly reflect carotenoid status in the body [50]. In our unique cohort of individuals following an attack of AP, there may be mechanistic differences in the absorption or utilisation of fat-soluble vitamins, such as carotenoids, compared with those with type 2 diabetes [51]. It is not uncommon for individuals to develop EPD following an attack of AP, which leads to maldigestion and malabsorption of nutrients, particularly of fat and fat-soluble vitamins [20,52]. It has also previously been established that there is an association between EPD and NODAP, where individuals with EPD have a significantly increased risk of developing NODAP [20]. It was suggested that deficiency in fat-soluble vitamins may have a role in this association as no significant correlation was found between exocrine pancreatic dysfunction and NODAP when individuals were taking fat-soluble vitamin supplements [20]. It is worth noting that pancreatic enzymes and serum carotenoid levels were not measured in the present study. Hence, we were not able to determine if EPD or low serum levels of these vitamins contributed to the observed results [53].
Vitamin D has two primary forms—vitamin D3 or cholecalciferol (which is endogenously synthesised in the skin after exposure to ultraviolet light) and vitamin D2 or ergocalciferol (which is predominantly obtained by dietary intake) [54]. Vitamin D2 and D3 are hydroxylated in the liver by vitamin D-25-hydroxylase to produce the major circulating form of vitamin D, 25-hydroxyvitamin D (25(OH)D) [55,56]. The serum concentration of 25(OH)D is one of the most reliable biomarkers of vitamin D status [56]. There are few foods with naturally occurring vitamin D and only 10–50% of the body’s vitamin D levels are obtained through dietary intake with the remainder being produced in the skin [57,58]. Vitamin D deficiency has been associated with the increased risk of cancer, obesity, osteoporosis, infectious and immune-mediated diseases, and cardiovascular disease [56]. It may also be involved with the onset of type 2 diabetes and impaired glucose metabolism. However, study results have been inconsistent. A large prospective case-control study found that dietary vitamin D intake was not significantly associated with the incidence of type 2 diabetes [59]. The Nurses’ Health Study found that no significant association between dietary vitamin D intake and type 2 diabetes [60]. However, a significant inverse relationship was observed between vitamin D supplementation and incident diabetes in women who consumed ≥400 UI/day of supplemental vitamin D [60]. These women had a 13% lower risk of developing diabetes, compared with those who consumed ≤100 UI/day of supplemental vitamin D [60]. A randomised controlled trial by Mitri et al. found that short-term cholecalciferol supplementation (2000 IU/day for 16 weeks), with or without calcium supplementation, improved β-cell function (as determined by a disposition index), insulin secretion, and attenuated the rise of HbA1c levels in adults at risk of type 2 diabetes [61]. In contrast, Gagnon et al. found that daily supplementation of 2000–6000 UI/day of cholecalciferol and calcium for six months resulted in no significant effect on insulin sensitivity (as determined by HOMA-S and Matsuda index), insulin secretion (as determined by insulinogenic index and C-peptide), and β-cell function (as determined by a disposition index), despite significant increase in circulating 25(OH)D [62]. A study of prediabetic individuals with vitamin D deficiency showed that 1200 IU/d of cholecalciferol and 500 mg of calcium for 16 weeks significantly increased mean serum 25(OH)D levels compared with the placebo. However, these did not improve insulin sensitivity (as determined by Stumvoll index and HOMA-IR), β-cell function (as determined by insulinogenic index), HbA1c, fasting glucose, or glucose tolerance [63]. Long-term vitamin D supplementation (2000 IU/week for five years) also had no significant effect on glucose metabolism or insulin resistance [64]. Therefore, evidence suggests that intake of vitamin D (either dietary or supplemental) has a limited effect on type 2 diabetes, glucose metabolism, and insulin resistance, irrespective of dosage or period of supplementation. Circulating vitamin D levels (25(OH)D) have been found to have an inverse association with the risk of type 2 diabetes in a meta-analysis of prospective studies [65]. Baseline serum 25(OH)D ≥50 nmol/L was significantly associated with decreased risk of type 2 diabetes [65]. Results from the study by Gao et al. also showed that circulating 25(OH)D had a positive association with insulin sensitivity (as determined by Matsuda index), a negative association with insulin resistance (as determined by HOMA-IR), and β-cell function (as determined by disposition Index) in women (but not men) with newly diagnosed type 2 diabetes [66].
The present study was the first to investigate the associations between habitual vitamin D intake and markers of glucose metabolism in individuals after an attack of AP. No significant associations were observed between dietary vitamin D intake and FPG, HOMA-IR, or HOMA-β. These results are consistent with evidence from other disease states, suggesting that vitamin D intake has little effect on diabetes risk and insulin traits; however, circulating serum vitamin D levels may indicate risk of NODAP. Sunlight exposure is the primary determinant of circulating 25(OH)D and overall vitamin D status; therefore, dietary intake may not reflect overall vitamin D status [57,58]. Vitamin D levels of AP patients have been found to be insufficient, deficient, or severely deficient in up to 40% of AP patients during hospital admission [67]. Serum 25(OH)D levels also decreased within the first two days of hospital admission [67]. Similarly, the prevalence of vitamin D insufficiency and deficiency was 28.5% and 56.2% in patients with AP, and these were associated with increased AP severity and risk of admission to the ICU [68]. Emerging evidence also demonstrates the perpetuation of low-grade inflammation long after the initial AP attack [65,69]. Therefore, the inflammatory state of AP may influence long-term fat-soluble vitamin status and may be associated with altered insulin traits. It is suggested that upregulation 1α-hydroxylase alters the synthesis of 1,25(OH)D by macrophages and tumour necrosis factor-α during inflammation, hence depleting the reservoir of 25(OH)D [67,70]. Based on the above arguments, further investigations on circulating vitamin D status and NODAP are warranted.

4.2. Water-Soluble Vitamins

Water-soluble vitamins are a group of structurally dissimilar, hydrophilic, organic compounds that include B vitamins and vitamin C [3,71]. Humans have evolutionarily lost the ability to endogenously synthesise most water-soluble vitamins (except for vitamin B3, which can be synthesised by gut bacteria in small quantities) [72,73]. Therefore, these vitamins must be obtained via dietary intake [71]. Water-soluble vitamins are not stored in large quantities throughout the body and are readily excreted through urine [3]. Therefore, short periods of inadequate water-soluble vitamin intake increases risk of vitamin deficiency [74]. Several potential causes of B vitamin deficiency include inadequate intake, increased requirements, malabsorption, drug [75].
Vitamin B3, also known as niacin, plays a role in energy metabolism, redox reactions, and reduce oxidative stress [76,77]. Dietary vitamin B3 is primarily in the form of nicotinic acid and nicotinamide; however some foods may contain small amounts of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) [78]. Nicotinamide can also be derived from the amino acid tryptophan, therefore foods high in tryptophan are also considered sources of vitamin B3 [78]. Vitamin B3 has a broad spectrum of biological functions, including serving as a cofactor for redox reactions, a substrate for enzymes, and a ligand for purine receptors [78]. Vitamin B3 also inhibits the production of the pro-inflammatory cytokines (hence, reducing inflammation) [73,79]. Studies investigating associations between dietary intake of vitamin B3 and diabetes and insulin traits are scarce, with inconsistent results. Eshak et al. observed an inverse relationship between vitamin B3 intake and diabetes in men and women; however, this association became non-significant after adjusting for alcohol intake and magnesium intake [14]. A study by Mancini et al. observed that dietary patterns with a positive loading for vitamin B3 and magnesium reduced the risk of developing type 2 diabetes, concluding that intakes high in vitamin B3 and magnesium may have a protective effect against type 2 diabetes when consumed together [80]. Niacin therapy has also been investigated in individuals with type 2 diabetes. It was shown that ≤2.5 g/day of niacin, alone or combined with statins, was effective in reducing cardiovascular events in those with diabetes [81]. Glycaemic control in the study cohort was mildly impaired with increases in fasting glucose by up to 5% and a 0.3% increase in HbA1c. However, these results were transient and reversible with antidiabetic medications [81]. More recent studies have also suggested that niacin treatment has a more significant effect on glucose levels in individuals with diabetes and may increase the risk of developing diabetes. A meta-analysis of randomised controlled trials found a 34% increase in the risk of developing diabetes in individuals who received niacin therapy [82]. Consistent results were observed in the HPS2-THRIVE study, with a 55% increase in significant disturbances in glycaemic control for individuals with diabetes taking extended-release niacin (compared with the placebo group) [83]. Additionally, those in the treatment group also had a 32% proportional increase in the diagnosis of diabetes compared with the placebo group [83]. Overall, evidence suggests that dietary intake of vitamin B3 may have limited effects on type 2 diabetes, particularly in women. The use of niacin therapy and pharmacological doses of vitamin B3 appears to negatively impact glycaemic control.
The present study found that reduced dietary intake of vitamin B3 was significantly directly associated with HOMA-β. Specifically, with every 1% decrease in vitamin B3 intake, HOMA-β decreased by 1.35% in individuals with NODAP. Therefore, it appears that insulin secretion in individuals with NODAP may be improved by increased vitamin B3 intake. However, the mechanisms behind the observed results are unclear. Vitamin B3 (specifically nicotinic acid) is well known for regulating dyslipidaemia and its effects on cardiovascular disease [78,84,85,86]. These effects are mediated by agonistic action of nicotinic acid on nicotinic acid G-protein-coupled pathway receptor GPR109a [78]. In adipocytes, activation of GPR109a suppresses the release of free fatty acids from adipose tissue, reducing free fatty acid flux to the liver, hence reducing the synthesis of triglyceride and VLDL production by substrate depletion [79]. It is not yet clear whether the observed derangements in glycaemic control with high dose niacin therapy is a side effect of increased GRP109a activation; however, use of low dose niacin therapy and dietary intake of vitamin B3 appear to not impact glucose homeostasis [78,87,88]. Chronically elevated lipid and lipoprotein profiles are associated with glucose intolerance, insulin resistance, and the onset of type 2 diabetes by inhibiting insulin-mediated glucose transporters in skeletal muscle [89,90,91,92]. Therefore, there may be a link between the GPR109a receptor, improved lipid homeostasis, and improved insulin secretion (though further investigations are required to validate this hypothesis). A previous study by the COSMOS group observed associations between lipid metabolism and individuals with chronic hyperglycaemia after AP [93]. In that study, chronic hyperglycaemia was significantly associated with elevated serum triglyceride and glycerol levels (consistent with findings in individuals with type 2 diabetes), yet not free fatty acids or apolipoprotein-B levels. The study also found that insulin and HOMA-IR were associated with lipid metabolism in patients after AP [93]. These results highlight the abnormal lipid profile of patients with chronic hyperglycaemia after an attack of AP and suggest that there may be a potential role for triglyceride-lowering pharmacotherapy in reducing the risk of NODAP [93]. Dietary vitamin B3 may improve insulin secretion and abnormal lipid profile of individuals after AP, reducing the risk of NODAP. However, pharmacological doses of vitamin B3 may have detrimental effects on glycaemic control in individuals with [83] and without diabetes [82,83]. Therefore, well-designed clinical studies are warranted to investigate these associations in people after an attack of AP.

4.3. Limitations

There are several limitations to consider within the present study. First, a self-administered FFQ was used to ascertain habitual intake of vitamins. Therefore, the possibility of recall bias cannot be discounted due to requiring the respondent to recall their diet retrospectively. Additionally, intentional or accidental over- or under-reporting of portion sizes and/or food frequency may also impact the accuracy of data [94]. However, the EPIC-Norfolk FFQ has been extensively validated in various populations, providing a more accurate representation of long-term vitamin intake compared with other dietary assessment methods [33,95]. Second, due to limitations of the EPIC-Norfolk FFQ and FETA software, intake of vitamin K and other vitamers and supplement intake were not able to be assessed [33]. Future studies should consider investigating other vitamins and vitamers in individuals after AP. Third, it is possible that dietary changes were made after an attack of AP, altering participant nutrient intake. However, FFQ data were collected an average of 26 months after an AP attack and are representative of a participant’s habitual intake of the past 12 months. Further, participants were not provided nutrition advice or encouraged to change their diet. Forth, vitamins/vitamers were investigated in isolation. Therefore, interactions between vitamins and other dietary confounders were not assessed. It is well known that nutrients and other dietary factors influence the bioavailability and absorption of other vitamins and impact glycaemic control and insulin traits [96,97,98]. However, due to the relatively small sample size of the present study, accounting for each of these covariates would result in the overfitting of statistical models. Therefore, the use of average daily energy intake was used as a single covariate to account for most other dietary variables, along with other covariates (age, sex, V/S fat volume ratio, smoking status, alcohol intake, aetiology of AP, number of AP episodes, cholecystectomy, use of antidiabetic medications). The V/S fat volume ratio was also used instead of more commonly used markers of adiposity (BMI and waist circumference), as it is a more comprehensive measure of abdominal adiposity and metabolic risk [99,100]. It is also worth noting that the use of antidiabetic medications was exclusive to the T2DM group and could affect results. Therefore, antidiabetic medications were included in statistical models. This study also did not assess other possible confounders (e.g., inflammatory markers, intra-pancreatic fat deposition), which may affect glucose metabolism and insulin traits following AP [101,102,103,104,105,106]. Due to the relatively small sample size of the present study and results not being corrected for multiple testing, there is a risk of type I error. Therefore, associations uncovered in this study should be externally validated by studies with larger sample size and adjust data for multiplicity. Additionally, the study cohort was predominantly made up of men, and the percentage of men in the NODAP group was significantly higher than that of the NAP group. It has previously been found that men have higher risk of developing NODAP compared with women [107]. This may be attributed to genetic variation between men and women, or difference in lifestyle factors such as alcoholism or smoking [107]. Although the present study did not investigate differences in vitamin/vitamer intake by sex, we included sex as a covariate. Fifth, habitual vitamin intake was assessed in this study, which is not necessarily reflective of vitamin status, particularly in a population that may be prone to malabsorption (such as NODAP) [20]. The vitamin status of an individual may affect insulin traits and glycaemic control; therefore, future studies should investigate vitamin levels in a post-pancreatitis population using more advanced assessment methods. Sixth, in this study, HOMA indices were used as markers of glucose metabolism. HOMA indices have been found to be a reliable indicator of glucose metabolism in individuals with impaired glucose tolerance, type 2 diabetes, and normoglycaemia [108]. However, HOMA indices may have limited accuracy in smaller study samples [108,109]. Therefore, future studies may consider using the hyperinsulinaemic-euglycaemic glucose clamp (the ‘gold standard’ for assessment of insulin traits) in exploring the associations between vitamin intake and glucose metabolism after an attack of AP [110]. Last, as this study had a cross-sectional design, a causal relationship between vitamin intake and NODAP cannot be established. However, in the first study investigating associations between vitamin intake and NODAP, we have provided insights that may assist the design of future studies of habitual vitamin intake in individuals after an attack of AP.

5. Conclusions

Of the 14 water-soluble and fat-soluble vitamins and vitamers investigated in the present study, habitual intake of α-carotene, β-carotene, total carotenoids and vitamin B3 was significantly directly associated with HOMA-β. The findings provide first evidence that intake of these vitamins/vitamers may have a role in NODAP. Longitudinal cohort and randomised controlled trials are now warranted to investigate causal relationships between these vitamins and NODAP as well as to unveil the mechanisms behind these associations, providing further evidence for nutrition interventions for individuals after an attack of AP.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14071480/s1, Table S1: Associations between habitual fat-soluble vitamin/vitamer intake and HOMA-IR in the study groups, Table S2: Associations between habitual water-soluble vitamin intake and HOMA-IR in the study groups.

Author Contributions

Conceptualisation and study design, M.S.P. Patient recruitment, W.K., S.H.B. and J.K. Data acquisition, C.F.N., W.K., J.K. and S.H.B. Analysis and interpretation of data, C.F.N. Statistical analysis, C.F.N. Drafting of manuscript, C.F.N. Revision of the manuscript, W.K., S.H.B., J.K. and M.S.P. Study supervision, M.S.P. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Royal Society of New Zealand (Rutherford Discovery Fellowship to Professor Max Petrov).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Health and Disability Ethics Committee (13/STH/182).

Informed Consent Statement

Informed consent was obtained from all participants involved in the study.

Data Availability Statement

The data are not publicly available due to the ethical conduct in human research regulations.

Acknowledgments

This study was part of the Clinical and epidemiOlogical inveStigations in Metabolism, nutritiOn, and pancreatic diseaseS (COSMOS) program.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Zhao, X.; Zhang, M.; Li, C.; Jiang, X.; Su, Y.; Zhang, Y. Benefits of Vitamins in the Treatment of Parkinson’s Disease. Oxid. Med. Cell. Longev. 2019, 2019, 9426867. [Google Scholar] [CrossRef] [PubMed]
  2. National Health and Medical Research Council (Australia); New Zealand Ministry of Health; Australian Department of Health and Ageing. Nutrient Reference Values for Australia and New Zealand; National Health and Medical Research Council: Canberra, Australia, 2006; ISBN 978-1-86496-237-6.
  3. Ofoedu, C.E.; Iwouno, J.O.; Ofoedu, E.O.; Ogueke, C.C.; Igwe, V.S.; Agunwah, I.M.; Ofoedum, A.F.; Chacha, J.S.; Muobike, O.P.; Agunbiade, A.O.; et al. Revisiting Food-Sourced Vitamins for Consumer Diet and Health Needs: A Perspective Review, from Vitamin Classification, Metabolic Functions, Absorption, Utilization, to Balancing Nutritional Requirements. PeerJ 2021, 9, e11940. [Google Scholar] [CrossRef] [PubMed]
  4. Aguilera-Méndez, A.; Boone-Villa, D.; Nieto-Aguilar, R.; Villafaña-Rauda, S.; Molina, A.S.; Sobrevilla, J.V. Role of Vitamins in the Metabolic Syndrome and Cardiovascular Disease. Pflugers Arch. Eur. J. Physiol. 2021, 474, 117–140. [Google Scholar] [CrossRef] [PubMed]
  5. Peterson, C.T.; Rodionov, D.A.; Osterman, A.L.; Peterson, S.N. B Vitamins and Their Role in Immune Regulation and Cancer. Nutrients 2020, 12, 3380. [Google Scholar] [CrossRef] [PubMed]
  6. Frei, B. Efficacy of Dietary Antioxidants to Prevent Oxidative Damage and Inhibit Chronic Disease. J. Nutr. 2004, 134, 3196S–3198S. [Google Scholar] [CrossRef]
  7. Bahadoran, Z.; Golzarand, M.; Mirmiran, P.; Shiva, N.; Azizi, F. Dietary Total Antioxidant Capacity and the Occurrence of Metabolic Syndrome and Its Components after a 3-Year Follow-up in Adults: Tehran Lipid and Glucose Study. Nutr. Metab. 2012, 9, 70. [Google Scholar] [CrossRef] [Green Version]
  8. Wei, J.; Zeng, C.; Gong, Q.; Li, X.; Lei, G.; Yang, T. Associations between Dietary Antioxidant Intake and Metabolic Syndrome. PLoS ONE 2015, 10, e0130876. [Google Scholar] [CrossRef]
  9. Cigerli, O. Vitamin Deficiency and Insulin Resistance in Nondiabetic Obese Patients. Acta Endocrinol. 2016, 12, 319–327. [Google Scholar] [CrossRef] [PubMed]
  10. Setola, E.; Monti, L.; Galluccio, E.; Palloshi, A.; Fragasso, G.; Paroni, R.; Magni, F.; Sandoli, E.; Lucotti, P.; Costa, S.; et al. Insulin Resistance and Endothelial Function Are Improved after Folate and Vitamin B12 Therapy in Patients with Metabolic Syndrome: Relationship between Homocysteine Levels and Hyperinsulinemia. Eur. J. Endocrinol. 2004, 151, 483–489. [Google Scholar] [CrossRef]
  11. Kayaniyil, S.; Retnakaran, R.; Harris, S.B.; Vieth, R.; Knight, J.A.; Gerstein, H.C.; Perkins, B.A.; Zinman, B.; Hanley, A.J. Prospective Associations of Vitamin D With β-Cell Function and Glycemia: The PROspective Metabolism and ISlet Cell Evaluation (PROMISE) Cohort Study. Diabetes 2011, 60, 2947–2953. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Bian, S.; Gao, Y.; Zhang, M.; Wang, X.; Liu, W.; Zhang, D.; Huang, G. Dietary Nutrient Intake and Metabolic Syndrome Risk in Chinese Adults: A Case–Control Study. Nutr. J. 2013, 12, 106. [Google Scholar] [CrossRef] [Green Version]
  13. Eshak, E.S.; Iso, H.; Muraki, I.; Tamakoshi, A. Fat-Soluble Vitamins from Diet in Relation to Risk of Type 2 Diabetes Mellitus in Japanese Population. Br. J. Nutr. 2019, 121, 647–653. [Google Scholar] [CrossRef] [PubMed]
  14. Eshak, E.S.; Iso, H.; Muraki, I.; Tamakoshi, A. Among the Water-Soluble Vitamins, Dietary Intakes of Vitamins C, B2 and Folate Are Associated with the Reduced Risk of Diabetes in Japanese Women but Not Men. Br. J. Nutr. 2019, 121, 1357–1364. [Google Scholar] [CrossRef] [PubMed]
  15. Zhou, C.; Na, L.; Shan, R.; Cheng, Y.; Li, Y.; Wu, X.; Sun, C. Dietary Vitamin C Intake Reduces the Risk of Type 2 Diabetes in Chinese Adults: HOMA-IR and T-AOC as Potential Mediators. PLoS ONE 2016, 11, e0163571. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Lankisch, P.G.; Apte, M.; Banks, P.A. Acute Pancreatitis. Lancet 2015, 386, 85–96. [Google Scholar] [CrossRef]
  17. Das, S.L.; Singh, P.P.; Phillips, A.R.; Murphy, R.; Windsor, J.A.; Petrov, M.S. Newly Diagnosed Diabetes Mellitus after Acute Pancreatitis: A Systematic Review and Meta-Analysis. Gut 2014, 63, 818. [Google Scholar] [CrossRef]
  18. Das, S.L.; Kennedy, J.I.; Murphy, R.; Phillips, A.R.; Windsor, J.A.; Petrov, M.S. Relationship between the Exocrine and Endocrine Pancreas after Acute Pancreatitis. World J. Gastroenterol. 2014, 20, 17196. [Google Scholar] [CrossRef]
  19. Berry, A.J. Pancreatic Enzyme Replacement Therapy During Pancreatic Insufficiency. Nutr. Clin. Pract. 2014, 29, 312–321. [Google Scholar] [CrossRef] [PubMed]
  20. Cho, J.; Scragg, R.; Pandol, S.J.; Petrov, M.S. Exocrine Pancreatic Dysfunction Increases the Risk of New-Onset Diabetes Mellitus: Results of a Nationwide Cohort Study. Clin. Transl. Sci. 2021, 14, 170–178. [Google Scholar] [CrossRef]
  21. Woodmansey, C.; McGovern, A.P.; McCullough, K.A.; Whyte, M.B.; Munro, N.M.; Correa, A.C.; Gatenby, P.A.C.; Jones, S.A.; de Lusignan, S. Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study. Diabetes Care 2017, 40, 1486–1493. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Petrov, M.S. Post-Pancreatitis Diabetes Mellitus: Prime Time for Secondary Disease. Eur. J. Endocrinol. 2021, 184, R137–R149. [Google Scholar] [CrossRef]
  23. Xiao, A.Y.; Tan, M.L.; Wu, L.M.; Asrani, V.M.; Windsor, J.A.; Yadav, D.; Petrov, M.S. Global Incidence and Mortality of Pancreatic Diseases: A Systematic Review, Meta-Analysis, and Meta-Regression of Population-Based Cohort Studies. Lancet Gastroenterol. Hepatol. 2016, 1, 45–55. [Google Scholar] [CrossRef]
  24. Cho, J.; Petrov, M.S. Pancreatitis, Pancreatic Cancer, and Their Metabolic Sequelae: Projected Burden to 2050. Clin. Transl. Gastroenterol. 2020, 11, e00251. [Google Scholar] [CrossRef]
  25. Cho, J.; Scragg, R.; Petrov, M.S. Postpancreatitis Diabetes Confers Higher Risk for Pancreatic Cancer Than Type 2 Diabetes: Results from a Nationwide Cancer Registry. Diabetes Care 2020, 43, 2106–2112. [Google Scholar] [CrossRef]
  26. Cho, J.; Scragg, R.; Petrov, M.S. Risk of Mortality and Hospitalization After Post-Pancreatitis Diabetes Mellitus vs Type 2 Diabetes Mellitus: A Population-Based Matched Cohort Study. Am. J. Gastroenterol. 2019, 114, 804–812. [Google Scholar] [CrossRef] [PubMed]
  27. Ley, S.H.; Hamdy, O.; Mohan, V.; Hu, F.B. Prevention and Management of Type 2 Diabetes: Dietary Components and Nutritional Strategies. Lancet 2014, 383, 1999–2007. [Google Scholar] [CrossRef] [Green Version]
  28. Evert, A.B.; Boucher, J.L.; Cypress, M.; Dunbar, S.A.; Franz, M.J.; Mayer-Davis, E.J.; Neumiller, J.J.; Nwankwo, R.; Verdi, C.L.; Urbanski, P.; et al. Nutrition Therapy Recommendations for the Management of Adults with Diabetes. Diabetes Care 2014, 37, S120–S143. [Google Scholar] [CrossRef] [Green Version]
  29. Norbitt, C.F.; Kimita, W.; Ko, J.; Bharmal, S.H.; Petrov, M.S. Associations of Habitual Mineral Intake with New-Onset Prediabetes/Diabetes after Acute Pancreatitis. Nutrients 2021, 13, 3978. [Google Scholar] [CrossRef]
  30. Kimita, W.; Li, X.; Ko, J.; Bharmal, S.H.; Cameron-Smith, D.; Petrov, M.S. Association between Habitual Dietary Iron Intake and Glucose Metabolism in Individuals after Acute Pancreatitis. Nutrients 2020, 12, 3579. [Google Scholar] [CrossRef]
  31. Petrov, M.S.; Windsor, J.A.; Lévy, P. New International Classification of Acute Pancreatitis: More Than Just 4 Categories of Severity. Pancreas 2013, 42, 389–391. [Google Scholar] [CrossRef]
  32. Petrov, M.S.; Basina, M. Diagnosing and Classifying Diabetes in Diseases of the Exocrine Pancreas. Eur. J. Endocrinol. 2021, 184, R151–R163. [Google Scholar] [CrossRef] [PubMed]
  33. Mulligan, A.A.; Luben, R.N.; Bhaniani, A.; Parry-Smith, D.J.; O’Connor, L.; Khawaja, A.P.; Forouhi, N.G.; Khaw, K.-T. A New Tool for Converting Food Frequency Questionnaire Data into Nutrient and Food Group Values: FETA Research Methods and Availability. BMJ Open 2014, 4, e004503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Singh, R.G.; Cervantes, A.; Kim, J.U.; Nguyen, N.N.; DeSouza, S.V.; Dokpuang, D.; Lu, J.; Petrov, M.S. Intrapancreatic Fat Deposition and Visceral Fat Volume Are Associated with the Presence of Diabetes after Acute Pancreatitis. Am. J. Physiol.-Gastrointest. Liver Physiol. 2019, 316, G806–G815. [Google Scholar] [CrossRef] [PubMed]
  35. Singh, R.G.; Nguyen, N.N.; DeSouza, S.V.; Pendharkar, S.A.; Petrov, M.S. Comprehensive Analysis of Body Composition and Insulin Traits Associated with Intra-Pancreatic Fat Deposition in Healthy Individuals and People with New-Onset Prediabetes/Diabetes after Acute Pancreatitis. Diabetes Obes. Metab. 2019, 21, 417–423. [Google Scholar] [CrossRef]
  36. Cervantes, A.; Singh, R.G.; Kim, J.U.; DeSouza, S.V.; Petrov, M.S. Relationship of Anthropometric Indices to Abdominal Body Composition: A Multi-Ethnic New Zealand Magnetic Resonance Imaging Study. J. Clin. Med. Res. 2019, 11, 435–446. [Google Scholar] [CrossRef] [Green Version]
  37. Stuart, C.E.; Singh, R.G.; Alarcon Ramos, G.C.; Priya, S.; Ko, J.; DeSouza, S.V.; Cho, J.; Petrov, M.S. Relationship of Pancreas Volume to Tobacco Smoking and Alcohol Consumption Following Pancreatitis. Pancreatology 2020, 20, 60–67. [Google Scholar] [CrossRef]
  38. Jenab, M.; Salvini, S.; van Gils, C.H.; Brustad, M.; Shakya-Shrestha, S.; Buijsse, B.; Verhagen, H.; Touvier, M.; Biessy, C.; Wallström, P.; et al. Dietary Intakes of Retinol, β-Carotene, Vitamin D and Vitamin E in the European Prospective Investigation into Cancer and Nutrition Cohort. Eur. J. Clin. Nutr. 2009, 63, S150–S178. [Google Scholar] [CrossRef] [PubMed]
  39. Petrov, M.S. Metabolic Trifecta After Pancreatitis: Exocrine Pancreatic Dysfunction, Altered Gut Microbiota, and New-Onset Diabetes. Clin. Transl. Gastroenterol. 2019, 10, e00086. [Google Scholar] [CrossRef]
  40. Ko, J.; Skudder-Hill, L.; Priya, S.; Kimita, W.; Bharmal, S.H.; Petrov, M.S. Associations between Intra-Pancreatic Fat Deposition, Pancreas Size, and Pancreatic Enzymes in Health and after an Attack of Acute Pancreatitis. Obes. Facts 2022, 15, 70–82. [Google Scholar] [CrossRef]
  41. Moltedo, A.; Álvarez-Sánchez, C.; Grande, F.; Charrondiere, U.R. The Complexity of Producing and Interpreting Dietary Vitamin A Statistics. J. Food Compos. Anal. 2021, 100, 103926. [Google Scholar] [CrossRef]
  42. Rao, A.; Rao, L. Carotenoids and Human Health. Pharmacol. Res. 2007, 55, 207–216. [Google Scholar] [CrossRef] [PubMed]
  43. Eggersdorfer, M.; Wyss, A. Carotenoids in Human Nutrition and Health. Arch. Biochem. Biophys. 2018, 652, 18–26. [Google Scholar] [CrossRef]
  44. Quansah, D.; Ha, K.; Jun, S.; Kim, S.-A.; Shin, S.; Wie, G.-A.; Joung, H. Associations of Dietary Antioxidants and Risk of Type 2 Diabetes: Data from the 2007–2012 Korea National Health and Nutrition Examination Survey. Molecules 2017, 22, 1664. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Sluijs, I.; Cadier, E.; Beulens, J.W.J.; van der A, D.L.; Spijkerman, A.M.W.; van der Schouw, Y.T. Dietary Intake of Carotenoids and Risk of Type 2 Diabetes. Nutr. Metab. Cardiovasc. Dis. 2015, 25, 376–381. [Google Scholar] [CrossRef] [PubMed]
  46. Ärnlöv, J.; Zethelius, B.; Risérus, U.; Basu, S.; Berne, C.; Vessby, B.; Alfthan, G.; Helmersson, J. Serum and Dietary β-Carotene and α-Tocopherol and Incidence of Type 2 Diabetes Mellitus in a Community-Based Study of Swedish Men: Report from the Uppsala Longitudinal Study of Adult Men (ULSAM) Study. Diabetologia 2009, 52, 97–105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Harari, A.; Coster, A.C.F.; Jenkins, A.; Xu, A.; Greenfield, J.R.; Harats, D.; Shaish, A.; Samocha-Bonet, D. Obesity and Insulin Resistance Are Inversely Associated with Serum and Adipose Tissue Carotenoid Concentrations in Adults. J. Nutr. 2020, 150, 38–46. [Google Scholar] [CrossRef] [Green Version]
  48. Mirmiran, P.; Khalili Moghadam, S.; Bahadoran, Z.; Tohidi, M.; Azizi, F. Association of Dietary Carotenoids and the Incidence of Insulin Resistance in Adults: Tehran Lipid and Glucose Study: Carotenoids and Insulin Resistance. Nutr. Diet 2016, 73, 162–168. [Google Scholar] [CrossRef]
  49. Higuchi, K.; Saito, I.; Maruyama, K.; Eguchi, E.; Mori, H.; Tanno, S.; Sakurai, S.; Kishida, T.; Nishida, W.; Osawa, H.; et al. Associations of Serum β-Carotene and Retinol Concentrations with Insulin Resistance: The Toon Health Study. Nutrition 2015, 31, 975–980. [Google Scholar] [CrossRef] [PubMed]
  50. Moran, N.E.; Mohn, E.S.; Hason, N.; Erdman, J.W.; Johnson, E.J. Intrinsic and Extrinsic Factors Impacting Absorption, Metabolism, and Health Effects of Dietary Carotenoids. Adv. Nutr. 2018, 9, 465–492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Ko, J.; Skudder-Hill, L.; Cho, J.; Bharmal, S.H.; Petrov, M.S. Pancreatic Enzymes and Abdominal Adipose Tissue Distribution in New-Onset Prediabetes/Diabetes after Acute Pancreatitis. World J. Gastroenterol. 2021, 27, 3357–3371. [Google Scholar] [CrossRef] [PubMed]
  52. Lindkvist, B.; Phillips, M.E.; Domínguez-Muñoz, J.E. Clinical, Anthropometric and Laboratory Nutritional Markers of Pancreatic Exocrine Insufficiency: Prevalence and Diagnostic Use. Pancreatology 2015, 15, 589–597. [Google Scholar] [CrossRef]
  53. Ko, J.; Cho, J.; Petrov, M.S. Low Serum Amylase, Lipase, and Trypsin as Biomarkers of Metabolic Disorders: A Systematic Review and Meta-Analysis. Diabetes Res. Clin. Pract. 2020, 159, 107974. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Lips, P. Vitamin D Physiology. Prog. Biophys. Mol. Biol. 2006, 92, 4–8. [Google Scholar] [CrossRef] [PubMed]
  55. Christakos, S.; Dhawan, P.; Verstuyf, A.; Verlinden, L.; Carmeliet, G. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol. Rev. 2016, 96, 365–408. [Google Scholar] [CrossRef] [PubMed]
  56. Hossein-nezhad, A.; Holick, M.F. Vitamin D for Health: A Global Perspective. In Mayo Clinic Proceedings; Elsevier: Amsterdam, The Netherlands, 2013; Volume 88, pp. 720–755. [Google Scholar]
  57. Hossein-nezhad, A.; Holick, M.F. Optimize Dietary Intake of Vitamin D: An Epigenetic Perspective. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 567–579. [Google Scholar] [CrossRef] [PubMed]
  58. Lips, P. Worldwide Status of Vitamin D Nutrition. J. Steroid Biochem. Mol. Biol. 2010, 121, 297–300. [Google Scholar] [CrossRef]
  59. Abbas, S.; Linseisen, J.; Rohrmann, S.; Beulens, J.W.J.; Buijsse, B.; Amiano, P.; Ardanaz, E.; Balkau, B.; Boeing, H.; Clavel-Chapelon, F.; et al. Dietary Vitamin D Intake and Risk of Type 2 Diabetes in the European Prospective Investigation into Cancer and Nutrition: The EPIC-InterAct Study. Eur. J. Clin. Nutr. 2014, 68, 196–202. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Pittas, A.G.; Dawson-Hughes, B.; Li, T.; Van Dam, R.M.; Willett, W.C.; Manson, J.E.; Hu, F.B. Vitamin D and Calcium Intake in Relation to Type 2 Diabetes in Women. Diabetes Care 2006, 29, 650–656. [Google Scholar] [CrossRef] [Green Version]
  61. Mitri, J.; Dawson-Hughes, B.; Hu, F.B.; Pittas, A.G. Effects of Vitamin D and Calcium Supplementation on Pancreatic β Cell Function, Insulin Sensitivity, and Glycemia in Adults at High Risk of Diabetes: The Calcium and Vitamin D for Diabetes Mellitus (CaDDM) Randomized Controlled Trial. Am. J. Clin. Nutr. 2011, 94, 486–494. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Gagnon, C.; Daly, R.M.; Carpentier, A.; Lu, Z.X.; Shore-Lorenti, C.; Sikaris, K.; Jean, S.; Ebeling, P.R. Effects of Combined Calcium and Vitamin D Supplementation on Insulin Secretion, Insulin Sensitivity and β-Cell Function in Multi-Ethnic Vitamin D-Deficient Adults at Risk for Type 2 Diabetes: A Pilot Randomized, Placebo-Controlled Trial. PLoS ONE 2014, 9, e109607. [Google Scholar] [CrossRef] [PubMed]
  63. Oosterwerff, M.M.; Eekhoff, E.M.; Van Schoor, N.M.; Boeke, A.J.P.; Nanayakkara, P.; Meijnen, R.; Knol, D.L.; Kramer, M.H.; Lips, P. Effect of Moderate-Dose Vitamin D Supplementation on Insulin Sensitivity in Vitamin D–Deficient Non-Western Immigrants in the Netherlands: A Randomized Placebo-Controlled Trial. Am. J. Clin. Nutr. 2014, 100, 152–160. [Google Scholar] [CrossRef] [PubMed]
  64. Mousa, A.; Naderpoor, N.; de Courten, M.P.; Teede, H.; Kellow, N.; Walker, K.; Scragg, R.; de Courten, B. Vitamin D Supplementation Has No Effect on Insulin Sensitivity or Secretion in Vitamin D–Deficient, Overweight or Obese Adults: A Randomized Placebo-Controlled Trial. Am. J. Clin. Nutr. 2017, 105, 1372–1381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Song, Y.; Wang, L.; Pittas, A.G.; Del Gobbo, L.C.; Zhang, C.; Manson, J.E.; Hu, F.B. Blood 25-Hydroxy Vitamin D Levels and Incident Type 2 Diabetes: A Meta-Analysis of Prospective Studies. Diabetes Care 2013, 36, 1422–1428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Gao, Y.; Wu, X.; Fu, Q.; Li, Y.; Yang, T.; Tang, W. The Relationship between Serum 25-Hydroxy Vitamin D and Insulin Sensitivity and β-Cell Function in Newly Diagnosed Type 2 Diabetes. J. Diabetes Res. 2015, 2015, 636891. [Google Scholar] [CrossRef] [PubMed]
  67. Bang, U.C.; Novovic, S.; Andersen, A.M.; Fenger, M.; Hansen, M.B.; Jensen, J.-E.B. Variations in Serum 25-Hydroxyvitamin D during Acute Pancreatitis: An Exploratory Longitudinal Study. Endocr. Res. 2011, 36, 135–141. [Google Scholar] [CrossRef] [PubMed]
  68. Huh, J.H.; Kim, J.W.; Lee, K.J. Vitamin D Deficiency Predicts Severe Acute Pancreatitis. United Eur. Gastroenterol. J. 2019, 7, 90–95. [Google Scholar] [CrossRef] [Green Version]
  69. Petrov, M.S. Panorama of Mediators in Postpancreatitis Diabetes Mellitus. Curr. Opin. Gastroenterol. 2020, 36, 443–451. [Google Scholar] [CrossRef] [PubMed]
  70. Inui, N.; Murayama, A.; Sasaki, S.; Suda, T.; Chida, K.; Kato, S.; Nakamura, H. Correlation between 25-Hydroxyvitamin D3 1α-Hydroxylase Gene Expression in Alveolar Macrophages and the Activity of Sarcoidosis. Am. J. Med. 2001, 110, 687–693. [Google Scholar] [CrossRef]
  71. Said, H.M. Intestinal Absorption of Water-Soluble Vitamins in Health and Disease. Biochem. J. 2011, 437, 357–372. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Fricker, R.A.; Green, E.L.; Jenkins, S.I.; Griffin, S.M. The Influence of Nicotinamide on Health and Disease in the Central Nervous System. Int. J. Tryptophan Res. 2018, 11, 117864691877665. [Google Scholar] [CrossRef] [Green Version]
  73. Yoshii, K.; Hosomi, K.; Sawane, K.; Kunisawa, J. Metabolism of Dietary and Microbial Vitamin B Family in the Regulation of Host Immunity. Front. Nutr. 2019, 6, 48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Sechi, G.; Sechi, E.; Fois, C.; Kumar, N. Advances in Clinical Determinants and Neurological Manifestations of B Vitamin Deficiency in Adults. Nutr. Rev. 2016, 74, 281–300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Porter, K.; Hoey, L.; Hughes, C.; Ward, M.; McNulty, H. Causes, Consequences and Public Health Implications of Low B-Vitamin Status in Ageing. Nutrients 2016, 8, 725. [Google Scholar] [CrossRef] [Green Version]
  76. Deshmukh, S.V.; Prabhakar, B.; Kulkarni, Y.A. Water Soluble Vitamins and Their Role in Diabetes and Its Complications. Curr. Diabetes Rev. 2020, 16, 649–656. [Google Scholar] [CrossRef] [PubMed]
  77. Sauve, A.A. NAD+ and Vitamin B3: From Metabolism to Therapies. J. Pharmacol. Exp. Ther. 2008, 324, 883–893. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  78. Hrubša, M.; Siatka, T.; Nejmanová, I.; Vopršalová, M.; Kujovská Krčmová, L.; Matoušová, K.; Javorská, L.; Macáková, K.; Mercolini, L.; Remião, F.; et al. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5. Nutrients 2022, 14, 484. [Google Scholar] [CrossRef]
  79. Lipszyc, P.S.; Cremaschi, G.A.; Zubilete, M.Z.; Bertolino, M.L.A.; Capani, F.; Genaro, A.M.; Wald, M.R. Niacin Modulates Pro-Inflammatory Cytokine Secretion. A Potential Mechanism Involved in Its Anti-Atherosclerotic Effect. Open Cardiovasc. Med. J. 2013, 7, 90–98. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Mancini, F.R.; Dow, C.; Affret, A.; Rajaobelina, K.; Dartois, L.; Balkau, B.; Bonnet, F.; Boutron-Ruault, M.-C.; Fagherazzi, G. Micronutrient Dietary Patterns Associated with Type 2 Diabetes Mellitus among Women of the E3N-EPIC (Etude Epidémiologique Auprès de Femmes de l’Education Nationale) Cohort Study. J. Diabetes 2018, 10, 665–674. [Google Scholar] [CrossRef]
  81. Goldberg, R.B.; Jacobson, T.A. Effects of Niacin on Glucose Control in Patients with Dyslipidemia. In Mayo Clinic Proceedings; Elsevier: Amsterdam, The Netherlands, 2008; Volume 83, pp. 470–478. [Google Scholar]
  82. Goldie, C.; Taylor, A.J.; Nguyen, P.; McCoy, C.; Zhao, X.-Q.; Preiss, D. Niacin Therapy and the Risk of New-Onset Diabetes: A Meta-Analysis of Randomised Controlled Trials. Heart 2016, 102, 198–203. [Google Scholar] [CrossRef] [PubMed]
  83. Landray, M.J.; Haynes, R.; Hopewell, J.C.; Parish, S.; Aung, T.; Tomson, J.; Wallendszus, K.; Craig, M.; Jiang, L.; Collins, R.; et al. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N. Engl. J. Med. 2014, 371, 203–212. [Google Scholar] [CrossRef] [Green Version]
  84. Julius, U.; Fischer, S. Nicotinic Acid as a Lipid-Modifying Drug—A Review. Atheroscler. Suppl. 2013, 14, 7–13. [Google Scholar] [CrossRef] [PubMed]
  85. Savinova, O.V.; Fillaus, K.; Harris, W.S.; Shearer, G.C. Effects of Niacin and Omega-3 Fatty Acids on the Apolipoproteins in Overweight Patients with Elevated Triglycerides and Reduced HDL Cholesterol. Atherosclerosis 2015, 240, 520–525. [Google Scholar] [CrossRef] [PubMed]
  86. Valdes-Ramos, R.; Laura, G.-L.; Elina, M.-C.; Donaji, B.-A. Vitamins and Type 2 Diabetes Mellitus. Endocr. Metab. Immune Disord. Drug Targets 2015, 15, 54–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Elam, M.B.; Hunninghake, D.B.; Davis, K.B.; Garg, R.; Johnson, C.; Egan, D.; Kostis, J.B.; Sheps, D.S.; Brinton, E.A.; for the ADMIT Investigators. Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients with Diabetes and Peripheral Arterial Disease: The ADMIT Study: A Randomized Trial. JAMA 2000, 284, 1263. [Google Scholar] [CrossRef] [Green Version]
  88. Grundy, S.M. Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated with Type 2 DiabetesResults of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch. Intern. Med. 2002, 162, 1568. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Bardini, G.; Dicembrini, I.; Rotella, C.M.; Giannini, S. Correlation between HDL Cholesterol Levels and Beta-Cell Function in Subjects with Various Degree of Glucose Tolerance. Acta Diabetol. 2013, 50, 277–281. [Google Scholar] [CrossRef] [PubMed]
  90. Seo, M.H.; Bae, J.C.; Park, S.E.; Rhee, E.J.; Park, C.Y.; Oh, K.W.; Park, S.W.; Kim, S.W.; Lee, W.-Y. Association of Lipid and Lipoprotein Profiles with Future Development of Type 2 Diabetes in Nondiabetic Korean Subjects: A 4-Year Retrospective, Longitudinal Study. J. Clin. Endocrinol. Metab. 2011, 96, E2050–E2054. [Google Scholar] [CrossRef] [Green Version]
  91. Ying, X.; Qian, Y.; Jiang, Y.; Jiang, Z.; Song, Z.; Zhao, C. Association of the Apolipoprotein B/Apolipoprotein A-I Ratio and Low-Density Lipoprotein Cholesterol with Insulin Resistance in a Chinese Population with Abdominal Obesity. Acta Diabetol. 2012, 49, 465–472. [Google Scholar] [CrossRef]
  92. Morakinyo, A.O.; Samuel, T.A.; Adekunbi, D.A.; Adegoke, O.A. Niacin Improves Adiponectin Secretion, Glucose Tolerance and Insulin Sensitivity in Diet-Induced Obese Rats. Egypt. J. Basic Appl. Sci. 2015, 2, 261–267. [Google Scholar] [CrossRef] [Green Version]
  93. Gillies, N.A.; Pendharkar, S.A.; Singh, R.G.; Asrani, V.M.; Petrov, M.S. Lipid Metabolism in Patients with Chronic Hyperglycemia after an Episode of Acute Pancreatitis. Diabetes Metab. Syndr. Clin. Res. Rev. 2017, 11, S233–S241. [Google Scholar] [CrossRef]
  94. Naska, A.; Lagiou, A.; Lagiou, P. Dietary Assessment Methods in Epidemiological Research: Current State of the Art and Future Prospects. F1000Research 2017, 6, 926. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Kowalkowska, J.; Slowinska, M.; Slowinski, D.; Dlugosz, A.; Niedzwiedzka, E.; Wadolowska, L. Comparison of a Full Food-Frequency Questionnaire with the Three-Day Unweighted Food Records in Young Polish Adult Women: Implications for Dietary Assessment. Nutrients 2013, 5, 2747–2776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Ko, J.; Kimita, W.; Skudder-Hill, L.; Li, X.; Priya, S.; Bharmal, S.H.; Cho, J.; Petrov, M.S. Dietary Carbohydrate Intake and Insulin Traits in Individuals after Acute Pancreatitis: Effect Modification by Intra-Pancreatic Fat Deposition. Pancreatology 2021, 21, 353–362. [Google Scholar] [CrossRef]
  97. Ko, J.; Skudder-Hill, L.; Tarrant, C.; Kimita, W.; Bharmal, S.H.; Petrov, M.S. Intra-Pancreatic Fat Deposition as a Modifier of the Relationship between Habitual Dietary Fat Intake and Insulin Resistance. Clin. Nutr. 2021, 40, 4730–4737. [Google Scholar] [CrossRef] [PubMed]
  98. Li, X.; Kimita, W.; Cho, J.; Ko, J.; Bharmal, S.H.; Petrov, M.S. Dietary Fibre Intake in Type 2 and New-Onset Prediabetes/Diabetes after Acute Pancreatitis: A Nested Cross-Sectional Study. Nutrients 2021, 13, 1112. [Google Scholar] [CrossRef] [PubMed]
  99. Kaess, B.M.; Pedley, A.; Massaro, J.M.; Murabito, J.; Hoffmann, U.; Fox, C.S. The Ratio of Visceral to Subcutaneous Fat, a Metric of Body Fat Distribution, is a Unique Correlate of Cardiometabolic Risk. Diabetologia 2012, 55, 2622–2630. [Google Scholar] [CrossRef] [Green Version]
  100. Ko, J.; Skudder-Hill, L.; Cho, J.; Bharmal, S.H.; Petrov, M.S. The Relationship between Abdominal Fat Phenotypes and Insulin Resistance in Non-Obese Individuals after Acute Pancreatitis. Nutrients 2020, 12, 2883. [Google Scholar] [CrossRef] [PubMed]
  101. Goodger, R.; Singaram, K.; Petrov, M.S. Prevalence of Chronic Metabolic Comorbidities in Acute Pancreatitis and Its Impact on Early Gastrointestinal Symptoms during Hospitalization: A Prospective Cohort Study. Biomed. Hub 2021, 6, 111–117. [Google Scholar] [CrossRef] [PubMed]
  102. Bharmal, S.H.; Kimita, W.; Ko, J.; Petrov, M.S. Cytokine Signature for Predicting New-Onset Prediabetes after Acute Pancreatitis: A Prospective Longitudinal Cohort Study. Cytokine 2022, 150, 155768. [Google Scholar] [CrossRef] [PubMed]
  103. Petrov, M.S.; Taylor, R. Intra-Pancreatic Fat Deposition: Bringing Hidden Fat to the Fore. Nat. Rev. Gastroenterol. Hepatol. 2022, 19, 153–168. [Google Scholar] [CrossRef]
  104. Nguyen, N.N.; Singh, R.G.; Petrov, M.S. Association between Intrapancreatic Fat Deposition and the Leptin/Ghrelin Ratio in the Fasted and Postprandial States. Ann. Nutr. Metab. 2022, 78, 14–20. [Google Scholar] [CrossRef] [PubMed]
  105. Singaram, K.; Gold-Smith, F.D.; Petrov, M.S. Motilin: A Panoply of Communications between the Gut, Brain, and Pancreas. Expert Rev. Gastroenterol. Hepatol. 2020, 14, 103–111. [Google Scholar] [CrossRef] [PubMed]
  106. Petrov, M.S. Post-Pancreatitis Diabetes Mellitus: Investigational Drugs in Preclinical and Clinical Development and Therapeutic Implications. Expert Opin. Investig. Drugs 2021, 30, 737–747. [Google Scholar] [CrossRef] [PubMed]
  107. Pendharkar, S.A.; Mathew, J.; Petrov, M.S. Age- and Sex-Specific Prevalence of Diabetes Associated with Diseases of the Exocrine Pancreas: A Population-Based Study. Dig. Liver Dis. 2017, 49, 540–544. [Google Scholar] [CrossRef] [PubMed]
  108. Bonora, E.; Targher, G.; Alberiche, M.; Bonadonna, R.C.; Saggiani, F.; Zenere, M.B.; Monauni, T.; Muggeo, M. Homeostasis Model Assessment Closely Mirrors the Glucose Clamp Technique in the Assessment of Insulin Sensitivity: Studies in Subjects with Various Degrees of Glucose Tolerance. Diabetes Care 2000, 23, 57–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  109. Kang, E.S.; Yun, Y.S.; Park, S.W.; Kim, H.J.; Ahn, C.W.; Song, Y.D.; Cha, B.S.; Lim, S.K.; Kim, K.R.; Lee, H.C. Limitation of the Validity of the Homeostasis Model Assessment as an Index of Insulin Resistance in Korea. Metabolism 2005, 54, 206–211. [Google Scholar] [CrossRef] [PubMed]
  110. Heise, T.; Zijlstra, E.; Nosek, L.; Heckermann, S.; Plum-Mörschel, L.; Forst, T. Euglycaemic Glucose Clamp: What It Can and Cannot Do, and How to Do It. Diabetes Obes. Metab. 2016, 18, 962–972. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Characteristics of the study cohort.
Table 1. Characteristics of the study cohort.
CharacteristicTotalNODAPT2DMNAPp *
(n = 106)(n = 37)(n = 37)(n = 32)
Age (years)56.1 (14.5)58.9 (14.4)57.2 (15.0)51.6 (13.3)0.094
Men, n (%)69 (65.1)26 (70.3)28 (75.7)15 (46.9)0.031
Daily energy intake (kcal)1686 (609)1776 (692)1728 (534)1534 (575)0.226
V/S fat volume ratio0.77 (0.43)0.81(0.40)0.87 (0.46)0.61 (0.40)0.035
Alcohol intake (g/day)11.08 (17.91)13.43 (21.90)8.65 (13.05)11.08 (17.70)0.527
Tobacco smoking 0.052
Yes23 (21.7)10 (27.0)4 (10.8)9 (28.2)
No82 (77.3)27 (72.9)32 (86.5)23 (71.9)
Aetiology of AP 0.563
Biliary40 (37.7)14 (37.8)14 (37.8)12 (37.5)
Non-biliary66 (62.3)23 (62.1)23 (62.1)20 (62.5)
Number of AP episodes1.85 (2.77)2.27 (3.76)1.43 (1.04)1.84 (2.82)0.434
Cholecystectomy 0.538
Yes39 (36.8)13 (35.1)12 (32.4)14 (43.8)
No66 (62.3)24 (64.9)25 (67.6)17 (53.1)
Anti-diabetic medication use <0.001
None92 (86.8)37 (100)23 (62.2)32 (100)
Oral medication8 (7.5)0 (0)8 (21.6)0 (0)
Insulin6 (5.7)0 (0)6 (16.2)0 (0)
Fasting plasma glucose (mmol/L)5.86 (1.74)5.86 (0.92)6.61 (2.55)4.96 (0.34)<0.001
HOMA-β (%)106.97 (56.87)95.74 (45.63)103.24 (57.12)125.07 (65.87)0.098
HOMA-IR (mIU/L-mmol/L)1.76 (1.28)1.73 (1.29)1.97 (1.31)1.55 (1.22)0.408
Fasting insulin (mU/L)16.68 (36.01)12.98 (9.96)24.62 (59.95)12.15 (10.27) 0.277
Abbreviations: AP = Acute pancreatitis. HOMA-IR = homeostasis model assessment of insulin resistance. HOMA-β = homeostasis model assessment of β-cell dysfunction. NAP = Normoglycaemia after acute pancreatitis. NODAP = New-onset diabetes or prediabetes after acute pancreatitis. T2DM = Type 2 diabetes or prediabetes prior to acute pancreatitis. V/S fat volume ratio = Visceral to subcutaneous fat volume ratio. Data are presented as mean (standard deviation) or frequency(percentage). * p values were calculated from one way ANOVA and represent the difference between groups. Significance was set at p < 0.05. Significant values are shown in bold.
Table
Table 2. Associations between habitual fat-soluble vitamin/vitamer intake and fasting plasma glucose in the study groups.
Table 2. Associations between habitual fat-soluble vitamin/vitamer intake and fasting plasma glucose in the study groups.
VitaminModelNAPT2DMNODAP
R²Unstandardised p95% CIR²Unstandardised p95% CIR²Unstandardised p95% CI
BLowerUpperBLowerUpperBLowerUpper
α-Carotene (µg)10.025−0.1160.400−0.3930.1620.062−0.8390.149−1.9930.3150.032−0.3410.292−0.9870.306
20.157−0.0830.571−0.3810.2150.085−0.8870.206−2.2870.5140.268−0.4860.110−1.0890.116
30.233−0.1070.458−0.4000.1860.105−0.7290.317−2.1940.7360.269−0.5070.115−1.1450.131
40.233−0.1110.510−0.4560.2330.260−0.3340.638−1.7761.1070.298−0.4780.146−1.1340.177
50.247−0.1370.488−0.5430.2690.5330.2660.690−1.0981.6300.330−0.4740.167−1.1590.211
β-Carotene (µg)10.039−0.1690.293−0.4910.1540.004−0.3390.716−2.2151.5370.037−0.6330.252−1.7370.471
20.162−0.1170.499−0.4670.2340.034−0.1070.926−2.4462.2320.254−0.7150.164−1.7370.306
30.229−0.1130.505−0.4560.2310.0750.2830.814−2.1522.7190.254−0.7140.176−1.7650.337
40.231−0.1240.538−0.5360.2880.2640.7350.528−1.6223.0920.286−0.6970.201−1.7890.394
50.243−0.1540.539−0.6680.3610.5561.2300.248−0.9183.3780.324−0.7510.193−1.9050.403
Retinol (µg)10.0890.2960.110−0.0710.6630.024−0.8630.370−2.7941.0680.0830.6660.084−0.0941.425
20.2210.3180.134−0.1040.7400.056−0.9430.413−3.2611.3750.2500.5820.180−0.2821.446
30.3210.3850.064−0.0250.7940.081−0.6040.618−3.0561.8470.2570.6330.160−0.2631.530
40.3500.4580.0460.0090.9070.260−0.5400.635−2.8511.7710.2890.6520.184−0.3281.632
50.3870.5680.0380.0331.1030.538−0.6720.520−2.8031.4580.3070.5450.309−0.5351.624
Total carotene (µg)10.037−0.1680.308−0.4990.1630.011−0.5850.549−2.5541.3830.043−0.6900.218−1.8060.426
20.161−0.1170.516−0.4810.2480.037−0.3760.750−2.7672.0140.262−0.7900.128−1.8210.241
30.229−0.1170.506−0.4740.2410.0730.0450.971−2.4772.5680.262−0.7940.138−1.8590.271
40.231−0.1270.542−0.5510.2980.2560.3770.748−2.0062.7600.294−0.7710.161−1.8660.325
50.243−0.1600.536−0.6920.3720.5370.6570.533−1.4902.8040.333−0.8310.153−1.9910.330
Total retinol
equivalents (µg)		10.013−0.1150.541−0.4960.2660.058−1.8120.162−4.3860.7620.0140.4710.492−0.9041.845
20.149−0.0620.769−0.4920.3680.082−1.9600.219−5.1501.2300.2070.1330.858−1.3741.640
30.216−0.0380.853−0.4620.3850.098−1.5150.377−4.9731.9420.2090.1910.808−1.3991.781
40.218−0.0210.930−0.4980.4570.272−1.3090.414−4.5501.9310.2470.3000.735−1.4932.093
50.227−0.0180.955−0.6890.6520.541−1.0850.446−3.9801.8090.2780.1250.898−1.8552.104
Vitamin D (µg)10.1010.3940.087−0.0610.8490.016−1.3740.468−5.1842.4360.0090.2760.587−0.7461.299
20.1820.3140.304−0.3020.9310.040−1.0250.651−5.6103.5590.213−0.3410.603−1.6630.981
30.2620.3650.223−0.2370.9670.078−0.8580.705−5.4473.7310.214−0.3430.606−1.6871.001
40.2660.3730.238−0.2651.0110.254−0.2250.917−4.5954.1450.256−0.4540.504−1.8280.919
50.2760.3750.271−0.3181.0690.5330.9080.659−3.2955.1100.304−0.7040.332−2.1670.760
Vitamin E (mg)10.079−0.4290.133−0.9980.1390.025−1.4690.368−4.7421.8040.0530.8880.169−0.3962.173
20.280−0.6910.040−1.349−0.0330.043−1.5940.599−7.7254.5370.226−1.0490.373−3.4151.317
30.308−0.6000.085−1.2880.0880.080−1.3690.652−7.5064.7680.226−1.0520.395−3.5401.436
40.308−0.5970.104−1.3250.1320.277−2.7260.357−8.6973.2450.277−1.4540.254−4.0111.103
50.320−0.6730.124−1.5490.2020.529−0.1560.959−6.3416.0290.299−1.1830.387−3.9471.582
Abbreviations: NAP = Normoglycaemia after acute pancreatitis. NODAP = New-onset diabetes or prediabetes after acute pancreatitis. T2DM = Type 2 diabetes or prediabetes prior to acute pancreatitis. 95% CI = 95% confidence interval. Data are presented as R2 values (from crude analysis), unstandardised B, p values (from linear regression) and 95% confidence intervals. All the variables were log-transformed. Model 1: unadjusted model. Model 2: age, sex, daily energy intake. Model 3: age, sex, daily energy intake, V/S fat volume ratio. Model 4: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status. Model 5: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status, aetiology of AP, number of AP episodes, cholecystectomy, use of antidiabetic medications. Significance was set at p < 0.05. Significant values are shown in bold.
Table
Table 3. Associations between habitual fat-soluble vitamin/vitamer intake and HOMA-β in the study groups.
Table 3. Associations between habitual fat-soluble vitamin/vitamer intake and HOMA-β in the study groups.
VitaminModelNAPT2DMNODAP
R²Unstandardised p95% CIR²Unstandardised p95% CIR²Unstandardised p95% CI
BLowerUpperBLowerUpperBLowerUpper
α-Carotene (µg)1 0.085 42.654 0.118 −11.525 96.833 0.026 12.369 0.380 −15.993 40.730 0.122 33.125 0.034 2.563 63.688
2 0.097 46.408 0.137 −15.817 108.633 0.067 11.596 0.509 −23.970 47.162 0.144 31.487 0.056 −0.863 63.836
3 0.120 49.019 0.123 −14.212 112.250 0.071 9.963 0.592 −27.775 47.701 0.161 35.211 0.042 1.280 69.143
4 0.149 42.815 0.238 −30.423 116.053 0.167 2.010 0.916 −37.064 41.083 0.265 39.096 0.023 5.803 72.390
5 0.253 46.748 0.245 −34.802 128.298 0.228 −2.449 0.918 −51.174 46.277 0.400 41.584 0.013 9.383 73.785
β-Carotene (µg)1 0.046 36.574 0.258 −28.244 101.392 0.017 16.025 0.479 −29.657 61.706 0.075 44.684 0.100 −9.036 98.405
2 0.062 41.825 0.260 −32.875 116.526 0.059 12.900 0.648 −44.502 70.302 0.111 43.746 0.117 −11.620 99.112
3 0.075 41.472 0.271 −34.421 117.365 0.064 9.766 0.744 −51.147 70.678 0.117 45.524 0.112 −11.213 102.261
4 0.105 23.914 0.586 −65.736 113.565 0.166 −0.629 0.984 −65.396 64.139 0.235 57.657 0.044 1.591 113.723
5 0.234 48.647 0.341 −55.638 152.933 0.229 −6.627 0.859 −83.196 69.942 0.360 60.440 0.035 4.672 116.209
Retinol (µg)1 0.028 33.740 0.374 −42.742 110.222 0.001 4.373 0.856 −44.366 53.112 0.000 −2.031 0.917 −41.393 37.331
2 0.048 44.359 0.341 −49.691 138.410 0.060 −14.040 0.628 −72.872 44.791 0.051 −14.781 0.537 −63.044 33.482
3 0.055 40.772 0.396 −56.658 138.202 0.076 −20.059 0.515 −82.446 42.329 0.051 −14.404 0.564 −64.723 35.916
4 0.124 45.228 0.382 −59.861 150.317 0.183 −20.912 0.488 −82.218 40.394 0.119 −0.939 0.972 −55.105 53.228
5 0.235 56.332 0.340 −64.138 176.803 0.246 −22.664 0.498 −91.238 45.911 0.249 −16.912 0.539 −72.685 38.860
Total carotene (µg)1 0.053 40.540 0.220 −25.715 106.796 0.013 15.205 0.527 −33.323 63.734 0.090 49.461 0.072 −4.580 103.502
2 0.072 47.608 0.217 −29.735 124.951 0.058 12.827 0.667 −47.733 73.387 0.124 48.182 0.088 −7.591 103.956
3 0.086 47.633 0.223 −30.889 126.155 0.063 9.133 0.775 −55.814 74.081 0.132 50.738 0.081 −6.625 108.102
4 0.112 31.256 0.488 −60.620 123.132 0.166 2.405 0.942 −65.244 70.054 0.241 59.620 0.039 3.231 116.009
5 0.247 58.189 0.269 −48.786 165.163 0.228 −0.725 0.985 −79.302 77.852 0.368 63.178 0.029 7.069 119.286
Total retinol
equivalents (µg)		10.04341.5830.269−33.984117.1500.02729.8230.371−37.24796.8930.00716.4170.630−52.06284.896
20.06150.2250.267−40.850141.3000.05513.1940.755−72.67599.0620.0405.2490.897−77.08587.583
30.07048.3950.293−44.571141.3600.0616.6550.885−86.884100.1940.0418.0650.851−78.82494.955
40.11134.1000.498−68.523136.7230.1661.3190.977−91.61994.2570.14947.0230.318−47.582141.628
50.26584.3300.196−47.518216.1780.228−2.0390.967−102.17798.0990.25436.8140.456−63.106136.734
Vitamin D (µg)10.00313.2460.781−83.424109.9160.025−44.0150.390−146.96558.9350.05635.1640.159−14.38584.712
20.02436.2650.587−99.552172.0820.116−80.6250.170−197.99936.7490.12760.9270.082−8.187130.041
30.03532.4720.634−106.445171.3880.128−82.3990.167−201.62436.8260.12860.8370.087−9.439131.113
40.10943.5500.531−98.202185.3030.291−115.9980.051−232.4560.4600.19256.5210.114−14.500127.542
50.21648.8520.491−96.631194.3350.347−122.8110.071−256.98911.3670.27542.0890.254−32.052116.231
Vitamin E (mg)10.00316.1830.783−103.121135.4880.06661.9030.156−24.999148.8060.01422.9580.478−42.09188.007
20.01623.4620.758−131.794178.7190.107100.7000.205−58.552259.9530.04834.9060.589−95.343165.154
30.02711.9890.882−152.544176.5220.11398.2540.225−64.290260.7980.05240.8720.546−95.836177.580
40.0922.7430.973−165.515171.0020.225105.9020.191−56.399268.2030.13244.7070.516−94.467183.881
50.21052.0210.574−138.296242.3380.25892.1140.374−119.097303.3260.27983.1410.230−56.011222.293
Abbreviations: HOMA-β = homeostasis model assessment β-cell function. NAP = Normoglycaemia after acute pancreatitis. NODAP = New-onset diabetes or prediabetes after acute pancreatitis. T2DM = Type 2 diabetes or prediabetes prior to acute pancreatitis. 95% CI = 95% confidence interval. Data are presented as R2 values (from crude analysis), unstandardised B, p values (from linear regression) and 95% confidence intervals. All the variables were log-transformed. Model 1: unadjusted model. Model 2: age, sex, daily energy intake. Model 3: age, sex, daily energy intake, V/S fat volume ratio. Model 4: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status. Model 5: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status, aetiology of AP, number of AP episodes, cholecystectomy, use of antidiabetic medications. Significance was set at p < 0.05. Significant values are shown in bold.
Table
Table 4. Associations between habitual water-soluble vitamin intake and fasting plasma glucose in the study groups.
Table 4. Associations between habitual water-soluble vitamin intake and fasting plasma glucose in the study groups.
VitaminModelNAPT2DMNODAP
R²Unstandardised p95% CIR²Unstandardised p95% CIR²Unstandardised p95% CI
BLowerUpperBLowerUpperBLowerUpper
Vitamin B1 (mg)10.002−0.0840.828−0.8670.7000.089−3.6820.081−7.8470.4830.0521.2270.177−0.5793.033
20.181−0.5730.313−1.7160.5710.121−5.0770.096−11.1040.9500.216−0.8560.537−3.6491.937
30.221−0.2820.648−1.5430.9780.143−4.6150.136−10.7741.5450.217−0.8750.535−3.7181.967
40.222−0.2520.712−1.6481.1440.368−6.0240.036−11.612−0.4370.265−1.3210.365−4.2571.615
50.234−0.3370.677−2.0031.3290.573−3.9300.137−9.2061.3460.311−1.7110.271−4.8361.414
Vitamin B2 (mg)10.0050.1440.716−0.6560.9430.106−4.2510.056−8.6130.1110.0911.9650.069−0.1614.091
20.1460.0190.972−1.0581.0950.176−6.6530.030−12.614−0.6910.2110.7180.648−2.4513.888
30.2190.1930.716−0.8881.2730.200−6.3130.041−12.347−0.2790.2130.7690.632−2.4744.011
40.2210.1840.741−0.9521.3190.357−5.7710.046−11.439−0.1040.2752.1980.272−1.8206.216
50.2290.1940.744−1.0301.4180.593−5.0560.070−10.5600.4480.3012.1030.368−2.6106.816
Vitamin B3 (mg)10.042−0.4420.277−1.2590.3750.055−3.3460.173−8.2371.5440.0290.8080.316−0.8042.421
20.295−1.1000.030−2.086−0.1150.095−4.7510.167−11.5942.0920.224−0.9430.400−3.1941.308
30.323−0.9720.062−1.9950.0510.132−4.6940.170−11.5172.1300.224−0.9300.415−3.2251.366
40.331−1.0140.066−2.0980.0710.276−3.0740.362−9.8813.7330.255−0.8530.509−3.4591.754
50.334−1.0580.096−2.3240.2080.531−1.0200.750−7.5725.5320.291−0.9310.488−3.6501.789
Vitamin B6 (mg)10.019−0.3200.466−1.2080.5670.051−3.2220.192−8.1411.6960.0260.9160.336−0.9922.824
20.242−1.1140.088−2.4040.1760.098−5.9760.154−14.3142.3620.239−1.5040.246−4.0961.089
30.274−0.9200.172−2.2670.4280.132−5.7170.172−14.0642.6310.239−1.4920.261−4.1501.167
40.275−0.9100.200−2.3370.5170.280−3.9670.322−12.0364.1010.268−1.3960.333−4.2971.505
50.291−1.0250.205−2.6610.6110.565−4.9420.183−12.3942.5100.301−1.3550.365−4.3801.669
Vitamin B9 (µg)10.016−0.1920.502−0.7700.3860.002−0.4300.813−4.1033.2420.0030.2700.742−1.3811.921
20.174−0.3140.365−1.0150.3870.0350.5300.836−4.6505.7110.258−1.3910.143−3.2770.495
30.237−0.2800.411−0.9710.4110.0760.7270.776−4.4505.9030.259−1.3850.151−3.3040.535
40.237−0.2760.454−1.0280.4750.2540.2510.917−4.6095.1100.274−1.1820.284−3.3961.032
50.259−0.4130.374−1.3620.5360.530−0.3270.879−4.7154.0610.316−1.3810.238−3.7280.967
Vitamin B12 (µg)10.0410.2810.283−0.2450.8080.270−5.2590.001−8.326−2.1930.0550.9260.164−0.3972.250
20.1530.1400.655−0.4970.7770.310−5.8950.002−9.372−2.4180.2120.3870.634−1.2532.026
30.2330.2310.457−0.4000.8630.319−5.6760.003−9.262−2.0900.2140.4200.615−1.2632.102
40.2330.2230.502−0.4550.9020.384−4.6980.024−8.723−0.6740.2500.4300.630−1.3782.239
50.2400.2130.573−0.5640.9900.593−3.4370.069−7.1690.2950.2810.3180.734−1.5892.225
Vitamin C (mg)10.052−0.2360.223−0.6250.1520.005−0.5100.677−2.9741.9550.005−0.2580.673−1.4860.971
20.201−0.2840.202−0.7300.1620.034−0.1290.926−2.9352.6770.242−0.7080.229−1.8830.468
30.255−0.2450.267−0.6900.2000.0740.1970.889−2.6653.0580.242−0.7030.240−1.9000.493
40.258−0.2680.284−0.7730.2380.253−0.0880.947−2.7782.6020.284−0.7560.214−1.9730.461
50.296−0.4410.190−1.1190.2380.540−0.8660.466−3.2821.5510.341−1.0340.127−2.3820.315
Abbreviations: NAP = Normoglycaemia after acute pancreatitis. NODAP = New-onset diabetes or prediabetes after acute pancreatitis. T2DM = Type 2 diabetes or prediabetes prior to acute pancreatitis. 95% CI = 95% confidence interval. Data are presented as R2 values (from crude analysis), unstandardised B, p values (from linear regression) and 95% confidence intervals. All the variables were log-transformed. Model 1: unadjusted model. Model 2: age, sex, daily energy intake. Model 3: age, sex, daily energy intake, V/S fat volume ratio. Model 4: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status. Model 5: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status, aetiology of AP, number of AP episodes, cholecystectomy, use of antidiabetic medications. Significance was set at p < 0.05. Significant values are shown in bold.
Table
Table 5. Associations between habitual water-soluble vitamin intake and HOMA-β in the study groups.
Table 5. Associations between habitual water-soluble vitamin intake and HOMA-β in the study groups.
VitaminModelNAPT2DMNODAP
R²Unstandardisedp95% CIR²Unstandardisedp95% CIR²Unstandardisedp95% CI
BLowerUpperBLowerUpperBLowerUpper
Vitamin B1 (mg)10.01142.7430.582−114.512199.9980.01032.8930.577−86.282152.0670.05562.6540.164−26.869152.178
20.051121.7550.322−126.508370.0180.05319.7780.811−148.017187.5730.131131.5360.076−14.439277.511
30.052111.2050.421−169.103391.5120.06113.5570.873−159.371186.4850.131131.0840.082−17.611279.778
40.10994.5530.522−206.688395.7930.17028.2410.739−144.743201.2260.226146.6350.054−2.996296.265
50.223131.1690.427−207.308469.6460.23440.2470.677−158.402238.8950.314127.9340.102−26.982282.850
Vitamin B2 (mg)10.02362.8370.427−96.935222.6090.05976.8670.180−37.390191.1240.000−1.5180.978−112.231109.196
20.068135.1160.231−91.641361.8730.09488.3740.271−72.907249.6550.042−25.6550.765−199.099147.790
30.073126.5990.282−110.736363.9350.09985.2310.298−79.789250.2510.043−23.9390.785−201.522153.644
40.140128.9520.278−111.612369.5170.19269.8960.390−94.709234.5010.13169.6270.519−148.701287.955
50.233119.3150.347−139.643378.2730.26395.1590.340−107.822298.1410.23810.6110.930−233.651254.873
Vitamin B3 (mg)10.02568.5870.405−97.535234.7080.01341.1050.536−92.863175.0720.03242.5270.287−37.389122.443
20.076144.8870.202−82.670372.4440.05735.9670.700−153.789225.7230.07970.4470.247−51.283192.178
30.079136.7250.253−103.996377.4470.06534.3280.718−158.689227.3450.08271.7520.247−52.247195.752
40.169167.7200.168−76.085411.5260.170−32.2710.750−238.848174.3060.245140.5860.03510.330270.842
50.342249.1970.054−4.603502.9970.232−38.6620.737−275.291197.9660.352134.9010.0415.816263.985
Vitamin B6 (mg)10.02979.7940.367−98.301257.8890.02553.3540.384−70.034176.7420.00418.6780.695−77.091114.447
20.106222.1570.118−60.324504.6370.06870.5710.488−135.447276.5890.04014.3550.841−130.214158.924
30.107215.6520.153−85.765517.0700.07668.2140.510−141.538277.9650.04216.4700.822−131.676164.616
40.164215.6520.153−85.765517.0700.17034.5550.741−178.907248.0170.13861.6930.426−94.618218.004
50.283240.8040.145−91.028572.6360.24070.4890.572−185.510326.4870.25965.9640.388−88.546220.475
Vitamin B9 (µg)10.03052.9840.356−62.696168.6650.01732.0510.479−59.229123.3320.01630.3390.454−51.071111.750
20.06687.7220.240−62.516237.9600.05416.6100.799−115.882149.1030.05740.8110.437−64.747146.369
30.07684.9730.264−68.271238.2170.06215.3550.817−119.424150.1330.05941.4020.438−65.998148.802
40.12065.4580.413−97.326228.2410.17123.0430.724−110.081156.1670.17379.2140.178−38.046196.473
50.23591.9100.335−102.621286.4410.23019.1290.801−137.147175.4050.28475.2580.206−44.048194.564
Vitamin B12 (µg)10.000−3.5240.947−111.910104.8630.07066.1470.144−23.970156.2630.0028.9790.789−58.52576.483
20.0125.7360.933−133.002144.4750.09456.7370.272−47.021160.4940.0390.9950.982−88.88590.874
30.0265.7360.933−133.002144.4750.09753.9180.312−53.464161.3000.0402.3050.960−89.97594.585
40.094−1.7860.980−145.308141.7360.16917.3440.780−109.359144.0480.13029.5260.537−67.152126.205
50.1979.4640.903−151.686170.6150.22913.2460.844−125.424151.9160.24117.2870.718−79.974114.548
Vitamin C (mg)10.04945.9960.240−32.526124.5190.02024.5300.440−39.47588.5360.06846.3390.120−12.699105.378
20.07862.6280.194−34.000159.2560.06422.6570.544−53.02998.3440.12052.9010.096−9.984115.786
30.08559.8480.226−39.561159.2570.07019.9040.606−58.55698.3640.12253.2640.099−10.682117.209
40.11641.5200.447−69.754152.7950.18631.2180.453−53.300115.7360.18347.7460.141−16.774112.266
50.23667.7590.332−74.766210.2830.25940.9540.367−51.682133.5910.29046.7950.178−22.697116.288
Abbreviations: HOMA-β = homeostasis model assessment β-cell function. NAP = Normoglycaemia after acute pancreatitis. NODAP = New-onset diabetes or prediabetes after acute pancreatitis. T2DM = Type 2 diabetes or prediabetes prior to acute pancreatitis. 95% CI = 95% confidence interval. Data are presented as R2 values (from crude analysis), unstandardised B, p values (from linear regression) and 95% confidence intervals. All the variables were log-transformed. Model 1: unadjusted model. Model 2: age, sex, daily energy intake. Model 3: age, sex, daily energy intake, V/S fat volume ratio. Model 4: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status. Model 5: age, sex, daily energy intake, V/S fat volume ratio, alcohol intake, smoking status, aetiology of AP, number of AP episodes, cholecystectomy, use of antidiabetic medications. Significance was set at p < 0.05. Significant values are shown in bold.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Norbitt, C.F.; Kimita, W.; Bharmal, S.H.; Ko, J.; Petrov, M.S. Relationship between Habitual Intake of Vitamins and New-Onset Prediabetes/Diabetes after Acute Pancreatitis. Nutrients 2022, 14, 1480. https://doi.org/10.3390/nu14071480

AMA Style

Norbitt CF, Kimita W, Bharmal SH, Ko J, Petrov MS. Relationship between Habitual Intake of Vitamins and New-Onset Prediabetes/Diabetes after Acute Pancreatitis. Nutrients. 2022; 14(7):1480. https://doi.org/10.3390/nu14071480

Chicago/Turabian Style

Norbitt, Claire F., Wandia Kimita, Sakina H. Bharmal, Juyeon Ko, and Maxim S. Petrov. 2022. "Relationship between Habitual Intake of Vitamins and New-Onset Prediabetes/Diabetes after Acute Pancreatitis" Nutrients 14, no. 7: 1480. https://doi.org/10.3390/nu14071480

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop